The P2Y12 receptor, activated by ADP, plays a central role in platelet activation that have proven therapeutic value. Clopidogrel is an antithrombic compound whose active metabolite is a selective, irreversible antagonist of P2Y12 receptor (IC50=100nM)[3]. Clopidogrel, administered during the last three months, significantly decreases blood glucose, collagen and fibronectin expression compared to vehicle-treated diabetic mice. Clopidogrel markedly ameliorates hyperglycemia-induced renal fibrosis[4]. The combination therapy of clopidogrel and aspirin (dual-antiplatelet therapy) has been shown to be significantly beneficial compared to aspirin monotherapy and has also shown to decrease sub-acute stent thrombosis as well as recurrent ischemic events following ACS[5].
搜索
